Literature DB >> 11357237

Pharmacology and immunology of botulinum toxin serotypes.

K R Aoki1.   

Abstract

Botulinum toxin preparations can provide patients with a therapeutic modality that may improve both their medical condition and quality of life. The mechanism of action of the various botulinum toxin preparations and serotypes is similar: they all block neurotransmitter release. The majority of clinical conditions treated are based upon the targeted temporary chemodenervation of the selected organ. The antinociceptive effects of botulinum toxin type A (BTX-A), based on preclinical studies and clinical experiences in treating movement disorders and other painful conditions, will also be reviewed to illustrate how this compound may act as it alleviates the discomfort associated with various conditions. Chronic therapies with preparations with the lowest amount of neurotoxin protein provide the best chance for long-term therapy by minimizing the potential of the patient to form neutralizing antibodies. Differences in formulations or serotypes impart unique efficacy and safety profiles and thus does not support a simple dose ratio conversion between products.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357237     DOI: 10.1007/pl00007816

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

Review 1.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

2.  Chronic eye movement induced pain and a possible role for its treatment with botulinum toxin.

Authors:  B J L Burton; S R Khan; J P Lee
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

3.  Botulinum toxin: poisoning the spastic bladder and urethra.

Authors:  Christopher P Smith; George T Somogyi; Michael B Chancellor
Journal:  Rev Urol       Date:  2002

Review 4.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

Review 5.  Treating headaches with botulinum toxin.

Authors:  Marco Aguggia
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 6.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 7.  Botulinum toxin for the treatment of musculoskeletal pain and spasm.

Authors:  Geoffrey Sheean
Journal:  Curr Pain Headache Rep       Date:  2002-12

8.  The Use of Botulinum Toxin Type A in Headache Treatment.

Authors:  Ninan T. Mathew; Alex O. Kaup
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

9.  Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment.

Authors:  Paul L Durham; Caleb G Masterson
Journal:  Headache       Date:  2012-10-23       Impact factor: 5.887

10.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.